A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase
10.3760/cma.j.issn.0578-1310.2019.02.010
- VernacularTitle: 伊马替尼治疗儿童慢性髓系白血病慢性期有效性和安全性分析
- Author:
Liqiang ZHANG
1
;
Jie ZHENG
;
Zhenping CHEN
;
Sidan LI
;
Jie MA
;
Runhui WU
Author Information
1. Hematology Oncology Center, Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China
- Publication Type:Clinical Trail
- Keywords:
Child;
Leukemia, myeloid, chronic-phase;
Cytogenetics
- From:
Chinese Journal of Pediatrics
2019;57(2):113-117
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of imatinib in the treatment of newly diagnosed chronic myeloid leukemia during chronic phase (CML-CP) in children and to analyze the difference of the efficacy and safety between imported original imatinib (Gleevec) and domestic generic imatinib (Xinwei).
Methods:Clinical data of 35 children with newly diagnosed CML-CP in Beijing Children′s Hospital from January 2014 to January 2018 were collected, among which 15 cases were treated with the imported original imatinib (original drug group) and 20 cases were treated with the domestic generic imatinib (generic drug group). The hematological, cytogenetic and molecular reactions and safety of the treatments were monitored at months 3, 6 and 12. Chi square test or rank sum test was used for the comparison between two groups.
Results:A total of 35 cases were treated for over 3 months, 31 cases were treated for over 6 months and 25 cases were treated for over 12 months. At 3 months, main cytogenetic response was obtained in 15 (100%) cases in the original drug group and 16 (80%) cases in the generic drug group respectively (χ2=3.387, P=0.119). At 6 months, complete cytogenetic response was obtained in 12 (80%) cases in the original drug group and 10 (63%) cases in the generic drug group (χ2=1.435, P=0.390). At 12 months, BCR-ABLIS ≤ 0.1% was obtained in 11 (92%) cases in the original drug group and 10 (77%) cases in the generic drug group (χ2=1.009, P=0.593). There was no significant difference at all stages (all P>0.05). Hematologic toxicity occurred in 7(20%) cases. The non-hematologic adverse reactions include nausea in 8 (23%) cases, pain in 8 (23%) cases, edema in 6 (17%) cases, emesis in 2 (6%) cases, fever in 2 (6%) cases, weakness in 1 (3%) case, rash in 1 (3%) case. The adverse reactions were easy to control and no drug toxicity related deaths occurred. There was no significant difference in the adverse reactions between original drug group and generic drug group (P>0.05).
Conclusions:Imatinib had a good efficacy and safety in the early treatment of newly diagnosed CML-CP in children. The efficacy and safety of generic imatinib is similar to that of imported imatinib.
